drugset
drugset / Trial / NCT06100510

PFA 100 Evaluation and Reference Interval HOACNY

NCT06100510 ↗

Phase 4 Enrolling by invitation 40 enrolled Hematology Oncology Associates of Central New York
Non-randomizedParallel-groupOpen-labelScreening

Summary

The purpose of this research is to evaluate instrument functionality and develop a reference range of normal data by healthy volunteers.

Timeline

Start
2024-02-19
Primary completion
2024-10-10
Completion
2024-10-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aspirin Small molecule 325 mg —

Indications

No indication recorded.